CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

ANDA 62-756 / S-025

***Name*:** Primaxin® I.V. in ADD-Vantage® vials
(Imipenem-Cilastatin Sodium for Injection)

***Sponsor*:** Merck Research Laboratories

***Approval Date*:** May 8, 1996

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 62-756 / S-025

CONTENTS

Reviews / Information Included in this Review	
Approval Letter	X
Tentative Approval Letter	
Labeling	
Labeling Reviews	
Medical Review(s)	
Chemistry Review	X
Bioequivalence Review(s)	
Statistical Review(s)	
Microbiology Reviews	X
Administrative Documents	
Correspondence	X

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 62-756 / S-025

APPROVAL LETTER

AADA 62-756/S-025

Merck Research Laboratories
Attention: Henrietta Ukwu, M.D.
P.O. Box 4, BLA-30A
West Point, PA 19486-0004

MAY 8 1996

Dear Madam:

This is in reference to your supplemental antibiotic application, dated October 13, 1995, submitted pursuant to Section 314.70 of the Regulations regarding your abbreviated antibiotic application for Primaxin® ADD-Vantage® (Imipenem-Cilastatin Sodium for Injection).

The supplemental application provides for use of an alternate facility (———————————————) for ———————— sterilization of the ADD-Vantage® breakaway cap.

We have completed the review of this supplemental application and it is approved.

We remind you that you must comply with the requirements for an approved abbreviated antibotic application described in 21 CFR 314.80-81.

The material submitted is being retained in our files.

Sincerely yours,

5/8/96

Frank O. Holcombe, Jr., Ph.D.
Director
Division of Chemistry II
Office of Generic Drugs
Center for Drug Evaluation and Research

APPEARS THIS WAY
ON ORIGINAL

cc: AADA 62-756/S-025
Division File
HFD-600/Reading File
HFD-82
FIELD COPY

Endorsements:

HFD-643/EDuffy/4/19/96/ EDuffy 5/3/96
HFD-643/JHarrison/4/19/96/ JHarrison 5/3/96
HFD-617/RWest/4/29/96/ RWest 5/3/96
X:\new\firmsam\merck\ltrs&rev\62756s25.apf
F/T by slm/5/2/96

Acceptable EER 11/21/95

SUPPLEMENT APPROVAL

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 62-756 / S-025

CHEMISTRY REVIEW

AADA 62-756/S-025

NAME AND ADDRESS OF APPLICANT:

Merck Sharp & Dohme Research Laboratories
Attn: Henrietta Ukwu, M.D.
Director Regulatory Affairs
P.O. Box 4, BLA-30A
West Point, PA 19486

Contact:
Henrietta Ukwu, M.D. (610)397-7176 or Bonnie J. Goldmann, M.D. (610)397-2383

PURPOSE OF AMENDMENT/SUPPLEMENT
The supplemental application provides for use of an alternate facility (————————————————) for ———— ———— sterilization of the ADD-Vantage® breakaway cap.

DATE OF SUBMISSION
October 13, 1995

PHARMACOLOGICAL CATEGORY
Antibiotic

TRADE NAME
Primaxin® I.V. ADD-Vantage®

NONPROPRIETARY NAME
Imipenem-Cilastatin Sodium

DOSAGE FORM
Powder for reconstitution

POTENCY
250, 500 mg

RX OR OTC
℞

SAMPLES
N/A

RELATED IND/NDA/DMF
50-587 Primaxin® IV
50-630 Primaxin® IM

STERILIZATION
The ———————————————— sterilization of the ADD-Vantage® breakaway cap has been found acceptable - see micro review dated 3/11/96 A.High.

LABELING
N/A

BIOEQUIVALENCY STATUS
N/A

ESTABLISHMENT INSPECTION
Acceptable EER # 9057 dated 11/21/95

COMPONENTS, COMPOSITION

COMPOSITION

COMPONENT	250/250	500/500
STERILE IMIPENEM MONOHYDRATE	—— mg *	—— mg ☼
STERILE CILASTATIN SODIUM	—— mg *	—— mg ☼
STERILE SODIUM BICARBONATE	10 mg	— mg
	—— mg	—— mg

* equivalent to 250 mg and —— % overage for Imipenem & Cilastatin
☼ equivalent to 500 mg and —— % overage for Imipenem & Cilastatin

MANUFACTURING
N/A

CONTROLS
N/A

PACKAGING
N/A

STABILITY
N/A

REMARKS AND CONCLUSION

RECOMMENDATION - APPROVABLE

RECALLS

Reviewer
Eric P. Duffy

Date Completed

The application covered by this review was taken in date order of receipt.

YES _X__ NO ___

cc: AADA 62-756/S-025
Division File
Field Copy
HFD-600/Reading File

Endorsements:

HFD-643/EDuffy/4/19/96/ EDuffy 5/3/96
HFD-643/JHarrison/4/19/96/ JHarrison 5/3/96
X:\new\firmsam\merck\ltrs&rev\62756s25.apf
F/T by slm/5/2/96

APPEARS THIS WAY
ON ORIGINAL

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 62-756 / S-025

MICROBIOLOGY REVIEWS

AADA 62-756/S025
AADA 62-757/S014

Microbiologist's Review #1

OFFICE OF GENERIC DRUGS HFD-640
Microbiologist s Review #1
March 8, 1996

Addendum to Microbiologist's Review #2

In reference to the Microbiologist's Review #2 dated March 14, 1995, [redacted], the approved supplement provides for an additional [redacted] sterilization facility for ADD-Vantage breakaway caps. A copy of the review will be placed in the appropriate volume of the following applications:

MSD (Merck) Subject of this review 10/19/95 (ASD)

AADA 62-756/S025 Cilastatin Sodium; Imipenem PDR

AADA 62-757/S014 Cefoxitin Sodium PDR

Andrea S. High 3/11/96

Andrea S. High, Ph. D.

3/13/9

cc:
Original AADA 62-756, 62-757
Duplicate AADA (s)
Division Copy
Field Copy
Drafted by A. High, HFD 640 x:wp\High\6275625m
Initialed by F. Fang or F. Holcombe

70-566
6.1

OFFICE OF GENERIC DRUGS, HFD640

Microbiologists Review #2

March 14, 1995

A. 1. ANDA: Supplemental Amendment to Supplements (Table Attached) for additional ——— facility for ADD-Vantage break away caps by ———.

APPLICANT [ ]

2. PRODUCT NAMES: See Attachment

3. DOSAGE FORM AND ROUTE OF ADMINISTRATION: Injection

4. METHOD(S) OF STERILIZATION: ———

B. 1. DATE OF INITIAL SUBMISSION: August 26, 1994

2. DATE OF AMENDMENT: January 31, 1995- **Subject of this review.**

3. RELATED DOCUMENTS: See attached list.
Form 483 - ——— referenced by applicant. Not in ANDA ———
———. response to 483 issued on ——— Not in ANDA ———

4. ASSIGNED FOR REVIEW: March 14, 1995.

C. REMARKS: ——— committed to provide data to the Supplement in their Dec. 7, 1994 response to the ——— "483". This Amendment fulfills that committment. A sterility assurance review was completed on Jan. 18, 1995 by a HFD 160 Review Microbiologist. The supplement was recommended for approval at that time. Since neither of the field correspondences were found in the jacket currently under review, this review is for the data provided in the Supplement Amendments only.

D. CONCLUSIONS: The submissions are recommended for approval on the basis of sterility assurance. Specific comments are provided in "E. Review Notes".

James L. McVey 3/15/95

3/20/95

cc:

Original ANDA
Division File
Field Copy
HFD 615 /CSO/W.P. Rickman
HFD 640 drafted by: J. McVey
HFD 640 initialed by F Fang or F Holcombe

APPEARS THIS WAY
ON ORIGINAL

Redacted 3 page(s)

of trade secret and/or

confidential commercial

information from

MICROBIOLOGY REVIEW #2

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 62-756 / S-025

CORRESPONDENCE

Henrietta N. Ukwu, M.D.
Director
Regulatory Liaison

Merck & Co., Inc.
P.O. Box 4, BLA-30A
West Point PA 19486-0004
Fax 610 397 2962
Tel 610 397 7176
215 652 5000

These copies are OFFICIAL FDA Copies not desk copies.

MERCK
Research Laboratories

October 13, 1995

Mr. John D. Harrison, Chief
Office of Generic Drugs, CDER, FDA
HFD-635, Room #MPN2
Document Control Room
5600 Fishers Lane
Rockville, Maryland 20857

NDA NO. _____ REF. NO. 50025
NDA SUPPL FOR Facility Rev

Dear Mr. Harrison:

Supplemental New Drug Application: AADA 62-756
PRIMAXIN™ in ADD-VANTAGE™ Vials
(Imipenem-Cilastatin Sodium for Injection)

Pursuant to Section 505(b) of the Food Drug and Cosmetic Act and in accordance with 21 CFR 314.70(b), we submit, for your approval, a supplement to AADA 62-756.

As indicated on the attached Form FDA 356h, the supplemental application provides for changes in Item 3 of the approved Abbreviated Antibiotic Application for PRIMAXIN™ in ADD-VANTAGE® Vials.

The supplement provides for an additional _____ facility, namely _____ _____, for sterilization of the ADD-VANTAGE™ breakaway cap. Please note that we have also sent to your attention concurrently a supplement to AADA 62-757 MEFOXIN™ in ADD-Vantage™ Vials covering the same change.

Attached is _____, Letter of Authorization to AADA _____ _____, allowing the Agency to utilize the data filed by _____ _____ with the Office of Generic Drugs, HFD #630 in support of this supplement. Additionally, appended is a copy of the Approval Letter dated _____, for ANDA _____ and other AADA/ANDA's.

Pursuant to 21 CFR 314.70(a) a complete field copy of this supplement has been submitted to the FDA Philadelphia District Office.

RECEIVED
OCT 19 1995
GENERIC DRUGS

Mailed 10-24-95

As required by Section 306(k)(1) of the Generic Enforcement Act [21 U.S.C. 335a(k)(1)], we hereby certify that, in connection with this application, Merck & Co., Inc. did not and will not use in any capacity the services of any person debarred under subsections 306(a) or (b) of the Act.

We consider the filing of this Supplemental New Drug Application to be a confidential matter, and request the Food and Drug Administration not to make its content, nor any future communications in regard to it, public without first obtaining the written permission of Merck & Co., Inc.

Questions concerning this supplemental application should be directed to Henrietta Ukwu, M.D. (610/397-7176) or, in my absence, to Bonnie J. Goldmann, M.D. (610/397-2383).

Sincerely,

Henrietta Ukwu, M.D.
Director
Regulatory Affairs

Q;YARB/SARF/LTR/ADA62756

Attachments

Certified No. P 914 183 906

Desk Copy: Philadelphia District Office, Food and Drug Administration Room 900
U.S. Custom House, 2nd & Chestnut Streets, Philadelphia, PA 19106-2973
Federal Express #1